Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.

Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Abstract Text:

    bohua liBohua Li,shu shiShu Shi,weizhu qianWeizhu Qian,lei zhaoLei Zhao,dapeng zhangDapeng Zhang,sheng houSheng Hou,lei zhengLei Zheng,jianxin daiJianxin Dai,jian zhaoJian Zhao,hao wangHao Wang,yajun guoYajun Guo,bohua liBohua Li,shu shiShu Shi,weizhu qianWeizhu Qian,lei zhaoLei Zhao,dapeng zhangDapeng Zhang,sheng houSheng Hou,lei zhengLei Zheng,jianxin daiJianxin Dai,jian zhaoJian Zhao,hao wangHao Wang,yajun guoYajun Guo,

    Despite the effectiveness of the anti-CD20 monoclonal antibody (mAb) Rituximab (C2B8) in the treatment of B-cell lymphoma, its efficacy remains variable and often modest. It seems likely that a combination of multiple mechanisms, such as complement-dependent cytotoxicity (CDC) and apoptotic signaling, underlies the therapeutic success of anti-CD20 mAbs. Unfortunately, all the current anti-CD20 mAbs effective in CDC are relatively inactive in signaling cell death and vice versa. In this study, we developed two genetically engineered tetravalent antibodies (TetraMcAb) respectively derived from the anti-CD20 mAbs C2B8 and 2F2. TetraMcAbs, with a molecular mass only 25 kDa higher than native divalent antibodies (DiMcAb), were shown not only to be as effective in mediating CDC and antibody-dependent cellular cytotoxicity against B-lymphoma cells as DiMcAbs but also to have antiproliferative and apoptosis-inducing activity markedly superior to that of DiMcAbs. Interestingly, whereas 2F2 and C2B8 were equally effective in inducing cell growth arrest and apoptosis, the functions of their tetravalent versions, 2F2(ScFvHL)(4)-Fc and C2B8(ScFvHL)(4)-Fc, were significantly different. 2F2(ScFvHL)(4)-Fc exhibited exceptionally more potent antiproliferative and apoptosis-inducing activity than that of C2B8(ScFvHL)(4)-Fc. Immunotherapeutic studies further showed that 2F2(ScFvHL)(4)-Fc was far more effective in prolonging the survival of severe combined immunodeficient mice bearing systemic Daudi or Raji tumors than C2B8, 2F2, and C2B8(ScFvHL)(4)-Fc, suggesting that it might be a promising therapeutic agent for B-cell lymphoma.

    Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Publishing Authors By Initials

    b liB Li,s shiS Shi,w qianW Qian,l zhaoL Zhao,d zhangD Zhang,s houS Hou,l zhengL Zheng,j daiJ Dai,j zhaoJ Zhao,h wangH Wang,y guoY Guo,b liB Li,s shiS Shi,w qianW Qian,l zhaoL Zhao,d zhangD Zhang,s houS Hou,l zhengL Zheng,j daiJ Dai,j zhaoJ Zhao,h wangH Wang,y guoY Guo,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Journal Published:

    PUBLICATION TYPE: Research Support, Non-U.S. Gov

    Journal: Cancer research

    VOLUME: 68

    Page Numbers: 2400-8

    Journal Abbreviation: Cancer Res.

    ISSN: 1538-7445

    DAY: 1

    MONTH: Apr

    YEAR: 2008

    Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 2984705

    Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.

    AFFILIATION: International Joint Cancer Institute, Second Military Medical University, Shanghai, People's Republic of China.

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Cancer Res

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News